DGCI gives nod for Covaxin Phase II/III trials on 2-18 year olds

The Indian drugs regulator, the Drugs Controller General of India (DCGI) has granted its approval to indigenously developed Covid-19 vaccine Covaxin’s developer Bharat Biotech for conducting Phase II/III clinical trials of the desi vaccine on children from 2 to 18 years of age. The children’s trials will be carried out on 525 healthy children volunteers with two doses.